Rapport's Seizure Drug Success Sparks Stock Surge
Rapport Therapeutics' experimental drug RAP-219 significantly reduced seizures in hard-to-treat epilepsy patients, leading to a 119.2% surge in its stock price, with the drug showing promising results and mild side effects.